drugset
drugset / Trial / NCT03584516

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516 ↗

Phase 2/3 Terminated 155 enrolled Incyte Corporation
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

Timeline

Start
2019-01-17
Primary completion
2023-11-03
Completion
2023-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule — Oral
Background Methylprednisolone Other / unclassified — —
Background Prednisone Other / unclassified — —

Indications

chronic graft versus host disease